Carcinoma

202 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Carcinoma
Treatment and conditionWhere it standsTrials
5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2) for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2) for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
APG-157 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
ASP2998 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Axelopran + pembrolizumab for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug Vedotin for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BHB810 for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, basosquamousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMX-001 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Breast Radiotherapy for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carbon ion irradiation for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy TIP for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Community Treatment for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Conventional Surgery + Intensity-Modulated Radiation Therapy + Quality-of-Life Assessment + Trametinib + PEMBROLIZUMAB + DABRAFENIB for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CP-383 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CYP Cocktail + ZIPALERTINIB for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
dabrafenib/trametinib for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + Gem/Cis for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for cholangiocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eliminating RT to the elective neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enfortumab vedotin + pembrolizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + Mevrometostat for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Erdafitinib + cetrelimab for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Evorpacept for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GALLIUM GA-68 GOZETOTIDE for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GCP intratumoral catheter for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GI-108 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hafnium oxide for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Haic+tae + tislelizumab + surufatinib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose Rate Brachytherapy + intra-lesional boost IMRT for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Izalontamab Brengitecan for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Loco-regional radiotherapy for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, giant cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, giant cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitomycin for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
N17350 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niacinamide for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + relatlimab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab and Ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OK-432 for carcinoma in situPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Osimertinib + Savolitinib for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxcel Q3W for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Padeliporfin for carcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
PD-1antibody plus GEMOX for klatskin tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Pemetrexed + AVELUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for carcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Petosemtamab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
PF-08634404 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prostate Radiotherapy + Radical Prostatectomy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pulmonary segmentectomy for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Reproductive organ sparing radical cystectomy for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rimegepant for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Savolitinib + Placebo for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Segmentectomy for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selective coverage radiotherapy for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selpercatinib for carcinoma, medullaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sequential cytoreductive intervention for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
SOC plus trastuzumab and pembrolizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin + Rilvegostomig for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sotorasib for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + Bemarituzumab for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + DEPATUXIZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + NIVOLUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + RAMUCIRUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + TRASTUZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talimogene Laherparepvec (T-VEC) for carcinoma, squamous cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tamoxifen for carcinoma, intraductal, noninfiltratingPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Trametinib + DABRAFENIB for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Transporter Cocktail + ZIPALERTINIB for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TTP-ICG fluorescent probe for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TYRA-300 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
vitamin D 25(OH)D for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VLS-1488 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for adenocarcinoma, clear cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vusolimogene Oderparepvec for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Zanzalintinib for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
zevor-cel for carcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zipalertinib for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zolbetuximab for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1